PAION announces last patient randomized in Phase III ischemic strokestudy (DIAS-2) with Desmoteplase
If it didn't have the clinical hold for 2 days the stock would now be double what it is trading for.
As people get comfortable that the trial is fully enrolled and the data should be out in 4 to 5 months for a stroke drug that could increase the window of therapy from 3 to 9 hours or more interest should get generated
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.